AKT1 and cancer: Although the castPCRTM AKT1 E17K assay performed well, the development of multi-gene panel approaches based on next-generation sequencing (NGS) for the selection of cancer patients for clinical studies is likely to replace single gene mutation assays for both clinical trial and therapy selection purposes [21].